Neurolief

Netanya, IsraelFounded 201311–50 employeesneurolief.com

Neuromodulation

Neurolief is a medical device company developing physician-directed, non-invasive neuromodulation therapies for neuropsychiatric and neurological disorders. Its flagship Proliv®Rx therapy is FDA-approved for major depressive disorder and is designed for use outside traditional clinical settings, while its Relivion®MG system addresses migraine treatment.

Visit neurolief.com ↗

FDA PMAFDA approval (PMA): 1
Founded: 2013
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Neurolief’s most significant recent milestone was the March 26, 2026, FDA-linked $6 million milestone-based investment from BrainsWay following approval of the Proliv®Rx System for major depressive disorder. The financing brought the company’s reported total funding to $31 million and supports broader access to physician-directed, at-home neuromodulation. On May 12, 2026, Neurolief introduced a dedicated Proliv®Rx website and presented the therapy in connection with APA 2026, emphasizing its clinical evidence, indication, and physician-supervised care model. On August 11, 2026, the company announced a new U.S. Department of Veterans Affairs contract intended to expand veterans’ access to prescription neuromodulation for depression and migraine. These developments indicate a shift from primarily technology and regulatory development toward commercialization, institutional contracting, and channel expansion. Earlier organizational changes also strengthened the operating team: Scott F. Drees became chief executive officer in December 2022, followed by Steve Beller’s appointment as chief commercial officer in October 2023.

Market position

Neurolief operates at the intersection of medical devices, digital health, mental health, and neuroscience. Its differentiation is the combination of a non-invasive, multi-channel neuromodulation platform with physician-directed care delivered outside traditional clinical settings. Proliv®Rx targets adults with major depressive disorder whose symptoms have not improved adequately with at least one antidepressant, while Relivion®MG extends the portfolio into migraine treatment. This gives Neurolief a broader neurological and neuropsychiatric scope than a single-indication device company. The model also combines hardware, treatment tracking, patient onboarding, technical support, and remote physician visibility, creating a care-delivery layer around the device. Its clearest market distinction is therefore operational: prescription neuromodulation designed for home use while retaining physician oversight. FDA approval for Proliv®Rx and the 2026 VA contract improve its institutional credibility, but reimbursement coverage, utilization, outcomes relative to alternative therapies, and scale remain important unresolved competitive variables.

Growth & opportunities

Neurolief’s trajectory shows a progression from platform development to regulated product commercialization. The company was founded in 2013 and raised a $1 million seed round in 2015, followed by a $9.5 million Series A in 2017. It then raised a $6.2 million Venture Round in December 2022 and a $3.3 million private equity round in September 2023. Additional convertible-note financing of $5 million in August 2025 and $6 million in March 2026 brought cumulative funding to $31 million. The March 2026 financing followed FDA approval of Proliv®Rx for adjunctive treatment of major depressive disorder, marking a clear inflection point from clinical and regulatory work toward market access. Product and distribution activity accelerated in 2026: a dedicated Proliv®Rx website launched on May 12, the therapy was promoted to clinicians and health systems around APA 2026, and an August 11 VA contract expanded the potential institutional channel. Leadership additions—Scott F. Drees as CEO in 2022 and Steve Beller as chief commercial officer in 2023—also align with commercialization. Employee growth, revenue, patient volumes, and hiring plans are not publicly quantified, limiting confidence about operating scale.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Neurolief distinct

reccy insights

What makes Neurolief distinct

01Proliv®Rx is described as the first and only FDA-approved prescription neuromodulation therapy for major depressive disorder that can be delivered outside traditional clinical settings.
02The platform supports both in-home and in-clinic use, enabling integration into existing physician workflows.
03Neurolief combines expertise in neuromodulation, psychiatry, neurology, biomedical engineering, and regulatory strategy.
04The portfolio spans neuropsychiatric and neurological indications, including depression and migraine.
05The company focuses on expanding access to clinically validated brain therapies for patients with unmet treatment needs.

Technology & products2

Technology & products

Proliv®Rx System
A prescription, non-invasive neuromodulation system for adjunctive treatment of major depressive disorder in adults whose depression has not improved adequately with at least one antidepressant.
Proliv®Rx Fulfillment and Physician-Supervised Care Program
A support and care-delivery service providing device fulfillment, patient onboarding, technical assistance, treatment tracking, and remote physician visibility for Proliv®Rx therapy.

Non-invasive, multi-channel brain neuromodulation platform
Proliv®Rx prescription neuromodulation therapy for major depressive disorder
Relivion®MG neuromodulation system for migraine treatment
Focal stimulation of neural pathways involved in mood and pain regulation

FDA regulatory

From FDA filings where Neurolief is the applicant

PMA· Class IIIClass III
ProlivRx System
Cranial Electrotherapy Stimulator To Treat Depression · P250010 · product code JXK
Approved Dec 31, 2025

Recent updates3

Launches, partnerships and team changes from press coverage

May 12, 2026Product launch
Neurolief launched a new Proliv Rx website providing clinicians, health systems, payors, and patients with information on the FDA-approved at-home brain stimulation therapy, clinical evidence, indication, and physician-supervised care model.
prnewswire.com
Oct 11, 2023Team change
Neurolief appointed neurotechnology business leader Steve Beller as chief commercial officer.
prnewswire.com
Dec 13, 2022Team change
Neurolief appointed neuromodulation industry leader Scott Drees as chief executive officer.
biospace.com

In the Cortex

Neurolief Receives FDA PMA Approval for Proliv Rx Therapyprnewswire.com · Jan 12, 2026

Similar companies

Show all 6 companies

About Neurolief

Products: Proliv®Rx System, Proliv®Rx Fulfillment and Physician-Supervised Care Program
Leadership: Brent Metzler, Chief Financial OfficerSteve Beller, Chief Commercial OfficerAmit Dar, Co-Founder & Chief Technology OfficerScott F. Drees, Chief Executive Officer
Focus areas: NeuroTechnology, medical devices, digital health, therapeutics, neuromodulation, brain therapy, depression treatment, migraine treatment
Headquarters: Netanya, Israel
Founded: 2013
Employees: 11–50
Patents granted: 16 (Crunchbase)
Trademarks: 6